DNA-cytometric parameters in patients with ovarian cancer

Aim. To study DNA flow cytometry parameters in patients with stage III-IV ovarian cancer receiving different treatments. Methods. Surgical material obtained from 93 female patients with verified stage III-IV ovarian cancer was studied. Patients were divided into 4 groups depending on the treatment variant: without neoadjuvant chemotherapy, with neoadjuvant chemotherapy, with neoadjuvant chemotherapy with different recombinant human interferon gamma (Ingaron) injections - intramuscular or intraperitoneal. Cell count was analyzed, and ploidy interpretation and cell cycle analysis were performed on fresh surgical material. Results. Differences in cell distribution depending on the treatment method were found. Increased proliferation rates, proliferation index, aneuploid tumors predominance in the group without drug exposure were demonstrated. Most of diploid tumours were registered in the group receiving neoadjuvant chemoimmunotherapy with intraperitoneal immunomodulator injections (83.4%) that indicates better disease prognosis. Under exposure to neoadjuvant polychemotherapy aneuploid cell number decreases to 38.4%, and chemoimmunotherapy with intramuscular and intraperitoneal recombinant human interferon gamma injections demonstrated even greater decrease - to 27.2 and 16.6%, respectively. Conclusion. Interferon gamma inclusion into the treatment contributes to a decreased number of aneuploid tumors, reduced proportion of aneuploid cells in tumors and reduced proliferation rates and proliferation index characterizing cancer aggressiveness.

рак яичников, ДНК-цитометрия, плоидность, химиоиммунотерапия, интерферон гамма